Real-World Use of Letermovir and Maribavir in Solid Organ Transplant: A Dual-Centre Study (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.20; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "While valganciclovir isfirst-line, resistance and side effects necessitate alternatives...Pre-LET resistance testing in 18 (47%) SP patients detectedganciclovir and/or cidofovir resistance in 11 (29%)... LET used as SP was limited bysignificant breakthrough and MBV treatment by resistance development in ~25% ofcases. Further studies are needed to identify patient-specific factors and CMVDNAemia thresholds to guide optimal use of these antivirals."
Clinical • Real-world • Real-world evidence • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
M. Xu; A. Wright; A. Mah; N. Matic; C. Lowe; W. Tsai; S. Belga
|